Search Result

Results for "

tuberculosis (TB)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (3) Antifolate (1) Autophagy (1) Bacterial (29) DNA/RNA Synthesis (1) Estrogen Receptor/ERR (1) mTOR (1) Phosphodiesterase (PDE) (1) Potassium Channel (1) Proton Pump (1) TNF Receptor (2)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Infection (30) Inflammation/Immunology (8) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1906

Streptomycin 25+ Cited Publications Agrept; Agrimycin; Streptomycin A	Antibiotic Bacterial	Infection Neurological Disease
Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

HY-112091

GSK2200150A	Bacterial	Infection
GSK2200150A, identified by high-throughput screening (HTS) campaign, is an anti-tuberculosis (TB) agent.

HY-112324

Terizidone	Bacterial	Infection
Terizidone is an antibacterial agent, and shows bacteriostatic activity. Terizidone can be used in tuberculosis (TB) research .

HY-151806

HadAB-IN-1	Bacterial	Infection Inflammation/Immunology
HadAB-IN-1 is a potent HadAB inhibitor. HadAB-IN-1 inhibits HadAB enzyme complexes activity with an IC₅₀ value of 0.03 μM. HadAB-IN-1 also affects mycolic acid biosynthesis in Mycobacterium tuberculosis* (Mtb). HadAB-IN-1 can be used for the research of tuberculosis* (TB) .

HY-152035

Mycobacterial Zmp1-IN-1	Bacterial	Infection Inflammation/Immunology
Mycobacterial Zmp1-IN-1 is a mycobacterial zinc metalloprotease-1 (Zmp1) inhibitor. Mycobacterial Zmp1-IN-1 has anti-mycobacterial activity for Mtb H37Ra in dose-dependent inhibition. Mycobacterial Zmp1-IN-1 can be used for the research of tuberculosis (TB) .

HY-B1906R

Streptomycin (Standard)	Antibiotic Bacterial	Infection Neurological Disease
Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

HY-146158

WX-081	Bacterial Potassium Channel Antibiotic	Infection
WX-081, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. WX-081 exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for agent susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. WX-081 also inhibits hERG channel with the IC50 of 1.89 μM.

HY-147661

DHFR-IN-2	Antifolate	Infection
DHFR-IN-2 (compound 4e) is a potent and uncompetitive inhibitor for MtDHFR (dihydrofolate reductase from M. tuberculosis), with an IC₅₀ of 7 μM. DHFR-IN-2 can be used for tuberculosis (TB) research .

HY-142031

4-Piperidinecarboxamide	Bacterial	Infection
4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNA synthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent .

HY-167242

ZTB23(R)	Bacterial	Infection
ZTB23(R) is a potent and selective Mycobacterium tuberculosis zinc metalloproteinase-1 (Zmp1) inhibitor with K_i value of 0.054 μM. ZTB23(R) can be used for tuberculosis (TB) research .

HY-111086

DG70 GSK1733953A	Bacterial	Infection
DG70 (GSK1733953A), a biphenyl amide, is a respiration inhibitor in Mycobacterium tuberculosis, inhibits MenG activity with an IC₅₀ value of 2.6 ± 0.6 μM. DG70 inhibits the catalytic methylation of Mycobacterium tuberculosis demethylmenaquinone methyltransferase enzymes. DG70 can be used for Tuberculosis (TB) research .

HY-126131

anti-TB agent 1	Bacterial	Infection
anti-TB agent 1 is a potent and orally active *anti-tuberculosis* agent, with MICs of < 2 nM against the Mtb strains H37Rv, rRMP and rINH .

HY-151354

Antibacterial agent 121	Bacterial	Infection
Antibacterial agent 121 (Compound 10) is an antibacterial agent. Antibacterial agent 121 shows anti-mycobacterial and anti-inflammatory activities and can be used in Tuberculosis (TB) research .

HY-114147

Tuberculosis inhibitor 3	Bacterial	Infection Inflammation/Immunology
Tuberculosis inhibitor 3 (compound 2i) displays potent anti-TB activity (MIC < 0.016 μg/mL) against agent-sensitive/resistant MTB strains. Tuberculosis inhibitor 3 (compound 2i) shows acceptable PK profiles with oral bioavailability .

HY-151514

Antituberculosis agent-5	Bacterial	Infection
Antituberculosis agent-5 (compound 52) is a nitrofuranylamide derivative, inhibits M. tuberculosis UDP-Gal mutase. Antituberculosis agent-5 inhibits Glf activity with an IC₅₀ value of 99 μM/mL and resists tuberculosis (TB) with a MIC value of 1.6 μg/mL .

HY-155460

Pks13-TE inhibitor 4	Bacterial	Infection
Pks13-TE inhibitor 4 (compound 44) is an oxadiazole series Pks13 inhibitor that effectively inhibits tuberculosis (TB) and resolves its drug resistance .

HY-147263

Dovramilast CC-11050	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .

HY-139987

LeuRS-IN-1	Bacterial	Infection
LeuRS-IN-1 is a potent, orally active M. tuberculosis leucyl-tRNA synthetase (M.tb LeuRS) inhibitor. LeuRS-IN-1 has IC₅₀ and Kd values of 0.06 μM, 0.075 μM for M.tb LeuRS, respectively . LeuRS-IN-1 inhibits human cytoplasmic LeuRS (IC₅₀=38.8 μM), and HepG2 protein synthesis (EC₅₀=19.6 μM) .

HY-139987A

LeuRS-IN-1 hydrochloride	Bacterial	Infection
LeuRS-IN-1 hydrochloride is a potent, orally active M. tuberculosis leucyl-tRNA synthetase (M.tb LeuRS) inhibitor. LeuRS-IN-1 hydrochloride has IC₅₀ and Kd values of 0.06 μM, 0.075 μM for M.tb LeuRS, respectively . LeuRS-IN-1 hydrochloride inhibits human cytoplasmic LeuRS (IC₅₀=38.8 μM), and HepG2 protein synthesis (EC₅₀=19.6 μM) .

HY-169916

GuaB-IN-1	Bacterial Estrogen Receptor/ERR	Infection
GuaB-IN-1 (Compound 15) exhibits high potency against M.tb with a MIC value of 0.25 μM. GuaB-IN-1 has a favorable 28% hERG inhibition profile at 10 μM. GuaB-IN-1 is promising for research of tuberculosis .

HY-125941

PNU-101603	Bacterial	Infection
PNU-101603 is a sulfoxide metabolite of Sutezolid (HY-10392). PNU-101603 alone or combined with SQ109 (HY-14989) shows excellent activity against Mycobacterium tuberculosis (MTB), as well as against agent-susceptible and multidrug-resistant TB .

HY-W013186S

Lansoprazole sulfide-d4 AG-1777-d₄	Proton Pump Bacterial	Inflammation/Immunology
Lansoprazole sulfide-d₄ is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 µM intracellularly and 0.46 µM in broth[1].

HY-125965

BioA-IN-13	Bacterial	Infection
BioA-IN-13 is a potent, cell permeable and whole-cell active inhibitor of Mycobacterium tuberculosis BioA enzyme .

HY-151598

Pks13-TE inhibitor 2	Bacterial	Infection
Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-151599

Pks13-TE inhibitor 3	Bacterial	Infection
Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-N10069

Bonducellin	Bacterial	Infection
Bonducellin is a a homoisoflavonoid, which can be isolated from Caesalpinia digyna roots. Bonducellin is a potent inhibitor of efflux pump (EP), while EP induces resistance in mycobacteria and serves as a target of anti-TB (tuberculosis) agents. Bonducellin reduces MIC of EtBr by 8-fold against M. smegmatis (MIC=62.5 mg/L) .

HY-147704

Antimycobacterial agent-2	Bacterial	Infection
Antimycobacterial agent-2 (compound 58) is a potent antimycobacterial agent. Antimycobacterial agent-2 shows anti-mycobacterial activities with an MIC₉₉ of 0.8 µM for Mycobacterium tuberculosis* (M.tb) H37Rv. Antimycobacterial agent-2 shows cytotoxic activities with an IC₅₀* of48.1 µM for CHO cells .

HY-111747

TBAJ-587	Bacterial	Infection Cardiovascular Disease
TBAJ-587, a potent *anti-tuberculosis* agent, inhibits M.tb strain H37Rv growth with MIC₉₀s of 0.006 and <0.02 μg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization .

HY-145931

CC214-2	mTOR Autophagy	Cancer
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .

HY-144727

Anti-inflammatory agent 11	Bacterial TNF Receptor	Infection Inflammation/Immunology
Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 11 inhibits Mtb H37Rv and M299 growth, with MIC₅₀ (minimum inhibitory concentration 50%) of 1.3 and 6.9 μM, respectively. Anti-inflammatory agent 11 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 11 can be used for tuberculosis (TB) research .

HY-144737

Anti-inflammatory agent 15	Bacterial TNF Receptor	Infection Inflammation/Immunology
Anti-inflammatory agent 15 (compound 29) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 15 inhibits Mtb H37Rv and M299 growth, with MIC₅₀ (minimum inhibitory concentration 50%) of 2.3 and 7.8 μM, respectively. Anti-inflammatory agent 15 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 15 can be used for tuberculosis (TB) research .

HY-105099

Rifalazil KRM-1648; ABI-1648	DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .

Cat. No.	Product Name

HY-L142

*Anti-tuberculosis* Compound Library**	109 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases. Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs. MCE supplies a unique collection of 109 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Anti-tuberculosis Compound Library

109 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 109 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.	Product Name	Category	Target	Chemical Structure